CY1105439T1 - Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση - Google Patents

Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση

Info

Publication number
CY1105439T1
CY1105439T1 CY20061100868T CY061100868T CY1105439T1 CY 1105439 T1 CY1105439 T1 CY 1105439T1 CY 20061100868 T CY20061100868 T CY 20061100868T CY 061100868 T CY061100868 T CY 061100868T CY 1105439 T1 CY1105439 T1 CY 1105439T1
Authority
CY
Cyprus
Prior art keywords
cells
autologous transplantation
culture methods
transplantation therapy
preparation
Prior art date
Application number
CY20061100868T
Other languages
Greek (el)
English (en)
Inventor
Alison Davies
Original Assignee
Hebe Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1105439(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hebe Limited filed Critical Hebe Limited
Publication of CY1105439T1 publication Critical patent/CY1105439T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/10—Mineral substrates
    • C12N2533/18—Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
CY20061100868T 1998-11-16 2006-06-26 Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση CY1105439T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9825096A GB2343679A (en) 1998-11-16 1998-11-16 Autologous transplantation and method for making cells dormant
PCT/GB1999/003813 WO2000029551A2 (en) 1998-11-16 1999-11-16 Cells, culture methods, and their use in autologous transplantation therapy

Publications (1)

Publication Number Publication Date
CY1105439T1 true CY1105439T1 (el) 2010-04-28

Family

ID=10842531

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061100868T CY1105439T1 (el) 1998-11-16 2006-06-26 Κυτταρα, μεθοδοι καλλιεργειας και η χρηση τους στη θepαπεια με αυτολογη μεταμοσχευση

Country Status (12)

Country Link
US (1) US20060246042A1 (OSRAM)
EP (1) EP1131408B1 (OSRAM)
JP (1) JP2002530293A (OSRAM)
AT (1) ATE321843T1 (OSRAM)
AU (1) AU775597B2 (OSRAM)
CY (1) CY1105439T1 (OSRAM)
DE (1) DE69930660T2 (OSRAM)
DK (1) DK1131408T3 (OSRAM)
ES (1) ES2262346T3 (OSRAM)
GB (1) GB2343679A (OSRAM)
PT (1) PT1131408E (OSRAM)
WO (1) WO2000029551A2 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0322806D0 (en) 2003-09-30 2003-10-29 Lifeforce Group Plc Cell bank for contingent autologous leukocyte transplantation
EP1711214A1 (en) 2004-02-02 2006-10-18 Interface Multigrad Technology (IMT) Ltd. Device for directional cooling of biological matter
JP4777908B2 (ja) 2004-02-02 2011-09-21 コア・ダイナミクス・リミテッド 生物学的材料ならびに生物学的材料の保存のための方法および溶液
ATE460947T1 (de) 2004-06-07 2010-04-15 Core Dynamics Ltd Verfahren zur sterilisation von biologischen präparaten
US8037696B2 (en) 2004-08-12 2011-10-18 Core Dynamics Limited Method and apparatus for freezing or thawing of a biological material
US8198085B2 (en) 2005-08-03 2012-06-12 Core Dynamics Limited Somatic cells for use in cell therapy
DE102007004855B4 (de) * 2007-01-31 2014-03-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Vorrichtung und Verfahren zur Deposition von biologischem Material in einem Zielsubstrat
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
EP2943206A4 (en) * 2013-01-12 2017-01-04 Cesca Therapeutics Inc. Rapid infusion of autologous bone marrow derived stem cells
ES2729640T3 (es) * 2013-10-24 2019-11-05 Neuroplast Beheer B V Procedimiento de reducción de la actividad inflamatoria de un trasplante de células madre y usos del mismo
CN105219709A (zh) * 2015-09-23 2016-01-06 上海吉泉生物技术有限公司 单采法建立免疫细胞库及应用
CL2016000753A1 (es) * 2016-03-31 2017-11-10 Fund Ciencia Para La Vida Atenuación de la neurodegeneración asociada a la enfermedad de parkison mediante la inhibición del receptor de dopamina d3 en células t cd4+.
JP6401818B2 (ja) * 2016-04-27 2018-10-10 株式会社金太郎ＣｅｌｌｓＰｏｗｅｒ 活性化幹細胞製造方法
DE102021116694B4 (de) * 2021-06-29 2023-03-09 Promocell Gmbh Wässrige Lösung zur Zellkonservierung
CN114984048A (zh) * 2022-06-16 2022-09-02 浙江百越生物技术有限公司 一种预防与治疗老年人行动迟缓的细胞疗法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004681B1 (en) * 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
JPH04282301A (ja) * 1991-03-08 1992-10-07 Kachiku Jiyuseiran Ishiyoku Gijutsu Kenkyu Kumiai 生物試料の急速凍結方法
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
AU6167394A (en) * 1993-01-27 1994-08-15 Hemosol Inc. Selective cell proliferation
AU8078894A (en) * 1993-10-08 1995-05-04 Cellpro Ii Methods for collection and cryopreservation of human granulocytes
US5866332A (en) * 1994-02-02 1999-02-02 Incyte Pharmaceuticals, Inc. Human myeloid terminal differentiation response gene
EP0668013B1 (en) * 1994-02-22 2005-04-20 Nippon Telegraph And Telephone Corporation Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same
US5704889A (en) * 1995-04-14 1998-01-06 Cobe Laboratories, Inc. Spillover collection of sparse components such as mononuclear cells in a centrifuge apparatus
US5865784A (en) * 1995-06-07 1999-02-02 Alliance Pharmaceutical Corp. Method of hemodilution facilitated by monitoring oxygenation status
US5922597A (en) * 1995-11-14 1999-07-13 Regents Of The University Of Minnesota Ex vivo culture of stem cells
JP2002515756A (ja) * 1997-01-31 2002-05-28 ヘモソル インク． 選択されたリンパ球の生産方法
AU6346898A (en) * 1997-03-06 1998-09-22 University Of Massachusetts Gene therapy using bone marrow transplants transfected with therapeutic genes under the control of tissue-specific promoters

Also Published As

Publication number Publication date
GB2343679A (en) 2000-05-17
DE69930660D1 (de) 2006-05-18
EP1131408A2 (en) 2001-09-12
PT1131408E (pt) 2006-08-31
DE69930660T2 (de) 2007-04-05
ATE321843T1 (de) 2006-04-15
AU775597B2 (en) 2004-08-05
US20060246042A1 (en) 2006-11-02
AU1068000A (en) 2000-06-05
WO2000029551B1 (en) 2001-01-11
DK1131408T3 (da) 2006-08-07
EP1131408B1 (en) 2006-03-29
WO2000029551A2 (en) 2000-05-25
JP2002530293A (ja) 2002-09-17
GB9825096D0 (en) 1999-01-13
WO2000029551A3 (en) 2000-10-19
ES2262346T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
CY1107453T1 (el) Baff, σχετικοι δεσμευτικοι παραγοντες και χρηση αυτων στη διεγερση και αναστολη β-κυτταρων και ανοσοσφαιρινων σε ανοσοαποκρισεις
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1107545T1 (el) Μεθοδοι για την προκληση θανατου καρκινικων κυτταρων και υποχωρησης του ογκου
ES2173314T3 (es) Metodos y composiciones para la modificacion selectiva de acidos nucleicos.
CY1113477T1 (el) Ετερολογος εκφραση πρωτεϊνων της neisseria
CY1115496T1 (el) Νευροτροφικος αυξητικος παραγοντας
ES2064355T3 (es) Procedimiento para cultivar celulas recombinantes.
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
CY1113600T1 (el) Θεραπειες συνδυασμου για λεμφωματα β-κυτταρου που περιλαμβανουν χορηγηση anti-cd20 αντισωματος
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
CY1106821T1 (el) Μεθοδος για την καλλιεργεια υποκαταστατου χονδρου και βιολογικη μητρα, παραγομενη συμφωνα με τη μεθοδο αυτη
CY1105758T1 (el) Τροποποιημενη απιμιναση αργινινης
DK1212422T3 (da) Humane CTLA-4-antistoffer og anvendelserne deraf
CY1105075T1 (el) Παραγωγα ινδολων και η χρησιμοποιηση τους σαν αναστολεις της φωσφοδιεστepασης 4
CY1104986T1 (el) Σταθερα σκευασματα παραγοντα viii
DE50214416D1 (de) Vermehrung von viren in zellkultur
CY1109207T1 (el) Διαδικασια εχινοκανδινης
CY1109221T1 (el) Χιμαιρικο γονιδιο που κωδικοποιει τους αντιγονικους καθοριστες τεσσαρων πρωτεϊνων του l. infantum
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
DK1082423T3 (da) Cyclin E2-gener og -proteiner